Given that previously developed P-gp inhibitors, including verapamil, are toxic to normal cells (5, 7, 8, 37), we believe that crizotinib and lapatinib are adequate alternatives for the sensitization of P-gp-overexpressing resistant cancer cells in clinical settings. The gene discussed is PGP; the disease is cancer.